<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3544">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898299</url>
  </required_header>
  <id_info>
    <org_study_id>6662</org_study_id>
    <nct_id>NCT01898299</nct_id>
  </id_info>
  <brief_title>TDCS for Auditory Hallucinations in Schizophrenia</brief_title>
  <official_title>tDCS for Auditory Hallucinations in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present research is to test a potential new treatment for auditory verbal&#xD;
      hallucinations in schizophrenia that uses transcranial Direct Current Stimulation (tDCS), a&#xD;
      neurostimulation technique that passes an extremely weak electric current through the brain.&#xD;
      During the treatment, two electrodes are positioned on the scalp above regions of the brain&#xD;
      implicated in abnormal cortical activity associated with auditory verbal hallucinations in&#xD;
      schizophrenia. Due to the directional flow of current, one electrode, termed&#xD;
      &quot;cathodal&quot;,inhibits cortical activity, and the other, termed &quot;anodal&quot;, increases cortical&#xD;
      activity. These electrodes will be placed such that cathodal stimulation is applied to an&#xD;
      area associated with hyperactivity and anodal stimulation to an area associated with&#xD;
      hypoactivity. One preliminary study has revealed that this form of neurostimulation can&#xD;
      alleviate auditory verbal hallucination symptoms both immediately following five days of&#xD;
      treatment and up to three months after the final treatment. The goal of this study is to&#xD;
      replicate these effects and explore the mechanisms that may underpin them.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      90 patients with persistent auditory verbal hallucinations will be recruited to this study.&#xD;
      Each individual will participate in behavioral assessments lasting up to 3 hours each and&#xD;
      will then be randomized to receive a series of active vs. sham tDCS treatments. For active&#xD;
      treatment, patients will have the inhibitory (cathodal) tDCS electrode placed over left&#xD;
      auditory cortex relative to an anodal placed over frontal cortex on the right side. tDCS&#xD;
      treatments will take place for 20 min per day for 5 consecutive days. For sham, procedures&#xD;
      will be similar except that sham (inactive) tDCS treatment will be used. Assessment batteries&#xD;
      will then be repeated following completion of treatment and at 1 and 3 mo following&#xD;
      treatment. In addition, patients will be offered the possibility to participate in a&#xD;
      concurrent magnetic resonance imaging (MRI) study aimed at evaluating the effects of tDCS on&#xD;
      activation of auditory cortex during an auditory discrimination task as well as on other&#xD;
      imaging parameters related to resting brain activity and metabolism. Patients who agree to&#xD;
      participate in this MRI study will be scanned before and after active or sham tDCS. In&#xD;
      addition, 5-15 schizophrenia patients will complete a week of High-density, e.g.,&#xD;
      &quot;high-definition&quot; tDCS (HD-tDCS) open label.&#xD;
&#xD;
      In addition to hallucinating patients, we will recruit up to 20 healthy controls and 20&#xD;
      non-hallucinating patients, who will have similar assessments to the patients, but will not&#xD;
      receive tDCS.&#xD;
&#xD;
      Overall, the investigators hypothesize that tDCS treatment will lead to reduction in&#xD;
      hallucinations, improvement in auditory function, and change in EEG and MRI measurements so&#xD;
      that patients more closely resemble healthy volunteers and non-hallucinating patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">August 14, 2018</completion_date>
  <primary_completion_date type="Actual">July 14, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Refractory Auditory Hallucinations</measure>
    <time_frame>Auditory Hallucination Rating Scale score after one month</time_frame>
    <description>Total score: Auditory hallucinations as determined by Auditory Hallucinations Rating Scale (AHRS). This is a seven item scale rating auditory hallucinations. Total score ranges from 1 to 41, with higher scores more severe.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Transcranial Direct Current Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial Direct Current Stimulation (tDCS)</intervention_name>
    <description>A neurostimulation technique that passes an extremely weak electric current through the brain.</description>
    <arm_group_label>Transcranial Direct Current Stimulation</arm_group_label>
    <other_name>BrainStim SYS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>Sham (inactive) tDCS treatment</description>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-55&#xD;
&#xD;
          -  Structured Clinical Interview for DSM Disorders (SCID) primary diagnosis of DSM-IV&#xD;
             (Diagnostic and Statistical Manual of Mental Disorders-Version IV) schizophrenia or&#xD;
             schizoaffective disorder&#xD;
&#xD;
          -  Persistent auditory verbal hallucinations&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  Stable antipsychotic medication for &gt; 4 weeks&#xD;
&#xD;
          -  Normal hearing&#xD;
&#xD;
          -  If female and not infertile, must agree to use one of the following forms of&#xD;
             contraception for the duration of study participation: systemic hormonal treatment, an&#xD;
             interuterine device (IUD) which was implanted at least 2 months prior to screening, or&#xD;
             &quot;double-barrier&quot; contraception&#xD;
&#xD;
          -  Willing/capacity to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Substance dependence or abuse (excluding nicotine) in the past 90 days&#xD;
&#xD;
          -  Current significant laboratory abnormality&#xD;
&#xD;
          -  History of seizure, epilepsy in self or fist degree relatives, stroke, brain surgery,&#xD;
             head injury with loss of consciousness &gt; 1 hour or clear cognitive sequelae,&#xD;
             intracranial metal implants, known structural brain lesion, devices that may be&#xD;
             affected by transcranial Direct Current Stimulation (tDCS) (pacemaker, medication&#xD;
             pump, cochlear implant, implanted brain stimulator)&#xD;
&#xD;
          -  Frequent and persistent migraines&#xD;
&#xD;
          -  History of adverse reaction to neurostimulation or open skin wounds that would&#xD;
             preclude safe placement of tDCS electrodes&#xD;
&#xD;
          -  Participation in study of investigational medication/device within 4 weeks&#xD;
&#xD;
          -  Current use of medications known to lower seizure threshold (lithium, serotonergic or&#xD;
             tricyclic antidepressants)&#xD;
&#xD;
          -  If female, pregnant or breast feeding at the time of screening&#xD;
&#xD;
          -  For MRI study only: Claustrophobia or metal implants or paramagnetic objects contained&#xD;
             within the body which may interfere with the MRI scan, as determined according to the&#xD;
             guidelines set forth in the following reference book: &quot;Guide to MR procedures and&#xD;
             metallic objects&quot; Shellock, PhD, Lippincott-Raven press, NY 1998&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C Javitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Kline Institute, New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan Kline Institute</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>January 31, 2020</results_first_submitted>
  <results_first_submitted_qc>March 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2020</results_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Joshua Kantrowitz</investigator_full_name>
    <investigator_title>Clinical Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallucinations</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT01898299/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT01898299/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transcranial Direct Current Stimulation</title>
          <description>Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days&#xD;
transcranial Direct Current Stimulation (tDCS): A neurostimulation technique that passes an extremely weak electric current through the brain.</description>
        </group>
        <group group_id="P2">
          <title>Sham tDCS</title>
          <description>Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.&#xD;
Sham tDCS: Sham (inactive) tDCS treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Post Treatment (One Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Post Treatment (One Month)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transcranial Direct Current Stimulation</title>
          <description>Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days&#xD;
transcranial Direct Current Stimulation (tDCS): A neurostimulation technique that passes an extremely weak electric current through the brain.</description>
        </group>
        <group group_id="B2">
          <title>Sham tDCS</title>
          <description>Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.&#xD;
Sham tDCS: Sham (inactive) tDCS treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="9.9"/>
                    <measurement group_id="B2" value="40.1" spread="8.6"/>
                    <measurement group_id="B3" value="39.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Auditory Hallucination Rating Scale (AHRS) total score</title>
          <description>This is a seven item scale rating auditory hallucinations. Total score ranges from 1 to 41, with higher scores more severe.</description>
          <units>units on a scale (total score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="5.7"/>
                    <measurement group_id="B2" value="25.2" spread="5.7"/>
                    <measurement group_id="B3" value="25.0" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Refractory Auditory Hallucinations</title>
        <description>Total score: Auditory hallucinations as determined by Auditory Hallucinations Rating Scale (AHRS). This is a seven item scale rating auditory hallucinations. Total score ranges from 1 to 41, with higher scores more severe.</description>
        <time_frame>Auditory Hallucination Rating Scale score after one month</time_frame>
        <population>Population at one month</population>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Direct Current Stimulation</title>
            <description>Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days&#xD;
transcranial Direct Current Stimulation (tDCS): A neurostimulation technique that passes an extremely weak electric current through the brain.</description>
          </group>
          <group group_id="O2">
            <title>Sham tDCS</title>
            <description>Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.&#xD;
Sham tDCS: Sham (inactive) tDCS treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Refractory Auditory Hallucinations</title>
          <description>Total score: Auditory hallucinations as determined by Auditory Hallucinations Rating Scale (AHRS). This is a seven item scale rating auditory hallucinations. Total score ranges from 1 to 41, with higher scores more severe.</description>
          <population>Population at one month</population>
          <units>AHRS total score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="9.9"/>
                    <measurement group_id="O2" value="23.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>ANCOVA</method>
            <method_desc>Control for Chlopromazine equivalents</method_desc>
            <param_type>Cohen's d effectsize</param_type>
            <param_value>0.48</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 day treatment</time_frame>
      <desc>Adverse events &gt;5%</desc>
      <group_list>
        <group group_id="E1">
          <title>Transcranial Direct Current Stimulation</title>
          <description>Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days&#xD;
transcranial Direct Current Stimulation (tDCS): A neurostimulation technique that passes an extremely weak electric current through the brain.</description>
        </group>
        <group group_id="E2">
          <title>Sham tDCS</title>
          <description>Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.&#xD;
Sham tDCS: Sham (inactive) tDCS treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joshua Kantrowitz</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467746738</phone>
      <email>jk3380@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

